0001213900-23-072599.txt : 20230831 0001213900-23-072599.hdr.sgml : 20230831 20230831071215 ACCESSION NUMBER: 0001213900-23-072599 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 42 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230831 DATE AS OF CHANGE: 20230831 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Can-Fite BioPharma Ltd. CENTRAL INDEX KEY: 0001536196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36203 FILM NUMBER: 231226964 BUSINESS ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 BUSINESS PHONE: 972 39241114 MAIL ADDRESS: STREET 1: 10 BAREKET STREET, KIRYAT MATALON STREET 2: P.O. BOX 7537 CITY: PETACH TIKVA STATE: L3 ZIP: 4951778 6-K 1 ea184381-6k_canfitebio.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of August 2023

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

10 Bareket Street

Kiryat Matalon, P.O. Box 7537

Petach-Tikva 4951778, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

This Report on Form 6-K, Exhibit 99.1, Exhibit 99.2 and the text under the heading “Financial Results” and “Forward-Looking Statements” in the press release in Exhibit 99.3 are hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File Nos. 333-227753 and 333-271384) and Form F-3 (File Nos. 333-195124, 333-236064, 333-249063 and 333-262055), to be a part there of from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

On August 31, 2023, Can-Fite BioPharma Ltd. (the “Company”) issued a press release announcing financial results for the six months ended June 30, 2023 and updates on its drug development programs. In addition, on the same day, the Company issued unaudited interim condensed consolidated financial statements as of June 30, 2023. Attached hereto and incorporated by reference herein are the following exhibits:

99.1		Operating and Financial Review and Prospects as of June 30, 2023

99.2		Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2023

99.3		Press Release dated August 31, 2023

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Exhibit Index

Exhibit No.		Description

99.1		Operating and Financial Review and Prospects as of June 30, 2023

99.2		Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2023

99.3		Press Release dated August 31, 2023

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 31, 2023	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

EX-99.1 2 ea184381ex99-1_canfitebio.htm OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2023

Exhibit 99.1

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

You should read the following selected financial data and discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K. Our financial statements are prepared in accordance with U.S. GAAP, and reported in U.S. dollars. We maintain our accounting books and records in U.S. dollars and our functional currency is the U.S. dollar. Certain amounts presented herein may not sum due to rounding. Unless the context requires otherwise, references in this report to “Can-Fite,” the “Company,” “we,” “us” and “our” refer to Can-Fite BioPharma Ltd, an Israeli company and our consolidated subsidiaries. “NIS” means New Israeli Shekel, and “$,” “US$,“U.S. dollars” and “USD” mean United States dollars.

Forward Looking Statements

The following discussion contains “forward-looking statements,” including statements regarding expectations, beliefs, intentions or strategies for the future. These statements may identify important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

	●	our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;

	●	uncertainties of cash flows and inability to meet working capital needs;

	●	the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts;

●

our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials;

●

our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals;

●

the clinical development, commercialization and market acceptance of our product candidates;

●

our ability to establish and maintain strategic partnerships and other corporate collaborations;

●

the implementation of our business model and strategic plans for our business and product candidates;

●

the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others;

	●	competitive companies, technologies and our industry;

	●	risks related to unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk;

	●	risks related to not satisfying the continued listing requirements of NYSE American; and

●

statements as to the impact of the political and security situation in Israel on our business.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of the 6-K to which this discussion is attached and are expressly qualified in their entirety by the cautionary statements included herein. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Glossary of Certain Terms

As used herein, unless the context otherwise requires:

●

references to “ADSs” refer to the Registrant’s American Depositary Shares;

●

references to “A3AR” refer to the A3 adenosine receptor;

●

references to “HCC” refer to hepatocellular carcinoma, also known as primary liver cancer;

	●	references to “ordinary shares,” “our shares” and similar expressions refer to the Company’s ordinary shares, no nominal (par) value per share; and

	●	references to the “SLD” are to the steatotic liver disease

Overview

We are a clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting the A3AR.

Our product pipeline is based on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues, but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman’s research revealed that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which bind with high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in tumor and inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators, currently our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate down-stream signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the inhibition of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate the body’s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result in disease.

Our product candidates, CF101, CF102 and CF602, are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known as Piclidenoson, is in an advance stage of clinical development for the treatment of autoimmune-inflammatory diseases, including psoriasis. During 2021, we decided to stop developing Piclidenoson for the treatment of COVID-19 to focus on other indications. CF102, also known as Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for the treatment of HCC in the United States and Europe. Namodenoson was granted Fast Track designation by the U.S. Food and Drug Administration, or FDA, as a second line treatment to improve survival for patients with advanced HCC who have previously received Nexavar (sorafenib). Namodenoson is also being developed for the treatment of SLD, a disease for which no FDA approved therapies currently exist. CF602 is our second generation allosteric drug candidate for the treatment of erectile dysfunction, which has shown efficacy in the treatment of erectile dysfunction in preclinical studies and we are investigating additional compounds, targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies revealed that our drug candidates have potential to treat additional inflammatory diseases, such as Crohn’s disease, oncological diseases, viral diseases, such as the JC virus, and obesity.

We believe our pipeline of drug candidates represent a significant market opportunity. For instance, according to iHealthcareAnalyst, the psoriasis drug market is forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC drug market in the G8 countries (U.S., Germany, France, Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.

We have in-licensed an allosteric modulator of the A3AR, CF602 from Leiden University. In addition, we have out-licensed the following product candidates for indications that we are currently pursuing:

●

Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including Hong Kong, Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma, for Central Eastern Europe, and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.

●

Namodenoson for the treatment of (i) liver cancer and SLD to Chong Kun Dang Pharmaceuticals, or CKD, for South Korea, (ii) advanced liver cancer and SLD to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC and SLD to Ewopharma, for Central Eastern Europe and Switzerland.

Currently, (i) we are doing the preparatory work for pivotal Phase III studies for Piclidenoson in the treatment of psoriasis following meetings with the FDA & EMA, (ii) we are conducting a pivotal Phase III trial for Namodenoson in the treatment of advanced liver cancer which is open for enrollment, (iii) we are conducting a Phase IIb study of Namodenoson in the treatment of SLD which is open for enrollment, (iv) we are doing the preparatory work for Phase IIb study of Namodenoson in the treatment of pancreatic cancer, (v) we are investigating additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile dysfunction, and (vi) we are conducting pre-clinical studies with formulations of cannabis components for the treatment of diseases in which there is an overexpression of A3AR. Since inception, we have incurred significant losses in connection with our research and development.

Moreover, we believe characteristics of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical activity, simple and less frequent delivery through oral administration and its low cost of production, position it well against the competition in psoriasis markets, where treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive and not always effective.

Like Piclidenoson, Namodenoson has a good safety profile, is orally administered and has a low cost of goods, which we believe may position it well in the HCC market, where no drug has yet been approved by the FDA for patients with advanced liver cancer disease defined as Child Pugh B7. In addition, pre-clinical studies show Namodenoson’s novel mechanism of action which entails de-regulation of three key signaling pathways which mediate the etiology and pathology of SLD and are responsible for the anti-inflammatory and anti-fibrogenic effect in the liver. Most recently, pre-clinical data support Namodenoson’s potential utilization as an anti-obesity drug.

Nevertheless, other drugs on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison to our drug candidates) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted by us, may all be competitive to the current drugs in our pipeline. In fact, some of these drugs are well established and accepted among patients and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are relatively safe. None of our product candidates have been approved for sale or marketing and, to date, there have been no commercial sales of any of our product candidates.

Results of Operations

Revenues

Revenues for the six months ended June 30, 2023 were $0.39 million compared to revenues of $0.41 million during the six months ended June 30, 2022. Revenues for the six months ended June 30, 2023 and June 30, 2022 comprised of recognition of a portion of advance payments received under distribution agreements with Gebro, CKD, Cipher and Ewopharma.

Research and development expenses

Research and development expenses for the six months ended June 30, 2023 were $3.41 million compared with $3.27 million for the same period in 2022. Research and development expenses for the first half of 2023 comprised primarily of expenses associated with the completion of the Phase 3 study of Piclidenoson for the treatment of psoriasis and two ongoing studies for Namodenoson, a Phase 3 study in the treatment of advanced liver cancer and a Phase 2b study for SLD. The increase is primarily due to an increase in expenses associated with Namodenoson.

General and administrative expenses

General and administrative expenses were $1.47 million for the six months ended June 30, 2023 compared to $1.57 million for the same period in 2022. The decrease is primarily due to the decrease in public and investor relations expenses and in directors and officer’s insurance policy premium. We expect that general and administrative expenses will remain at the same level through 2023.

Financial income, net

Financial income, net for the six months ended June 30, 2023 was $0.27 million compared to financial expense, net of $0.18 million for the same period in 2022. The decrease in financial expense, net was mainly due to revaluation of our short-term investment and increase in interest income from deposits in 2023.

Liquidity and Capital Resources

Since inception, we have funded our operations primarily through public (in Israel and US) and private offerings of our equity securities and payments received under our strategic licensing arrangements. As of June 30, 2023, we had approximately $9.60 million in cash, cash equivalents and short-term deposits, and have invested most of our available cash funds in ongoing cash accounts.

We may be able to use U.S. taxes withheld as credits against Israeli corporate income tax when we have income, if at all, but there can be no assurance that we will be able to realize the credits. In addition, we believe that we may be entitled to a refund of such withholding tax from the U.S. government but there can be no assurance that we will be entitled to such a refund.

Net cash used in operating activities was $5.04 million for the six months ended June 30, 2023, compared with net cash used in operating activities of $6.07 million for the same period in 2022. The $1.03 million decrease in the net cash used in operating activities during the six months ended June 30, 2023 compared to the same period in 2022, was mainly due to higher costs in 2022 due to completion of the Phase III study of Piclidenoson for the treatment of psoriasis in during 2022.

Net cash used in investing activities for the six months ended June 30, 2023 was $1.00 million compared with net cash provided by investing activities of $3.49 million for the same period in 2022. The $4.49 million decrease in the net cash provided by investing activities during the six months ended June 30, 2023 compared to the same period in 2022, was mainly due to maturity in short term deposit.

Net cash provided by financing activities was $6.52 million for the six months ended June 30, 2023 compared to no net cash provided by financing activities for the same period in 2022. Net cash provided by financing activities for the six months ended June 30, 2023 was due to proceeds from issuance of share capital and warrants.

Developing drugs, conducting clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. Although we believe our existing financial resources as of the date of issuance of this Form 6-K, will be sufficient to fund our projected cash requirements at least through the next twelve months, we will require significant additional financing to fund our operations. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements will depend on many factors, including:

	●	the level of research and development investment required to develop our product candidates;

	●	the failure to obtain regulatory approval or achieve commercial success of our product candidates, including Piclidenoson, Namodenoson and CF602;

●

the results of our preclinical studies and clinical trials for our earlier stage product candidates, and any decisions to initiate clinical trials if supported by the preclinical results;

●

the costs, timing and outcome of regulatory review of our product candidates that progress to clinical trials;

	●	our ability to partner or sub-license any of our product candidates;

	●	the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued patents and defending intellectual property-related claims;

●

the cost of commercialization activities if any of our product candidates are approved for sale, including marketing, sales and distribution costs;

●

the cost of manufacturing our product candidates and any products we successfully commercialize;

●

the timing, receipt and amount of sales of, or royalties on, our future products, if any;

●

the expenses needed to attract and retain skilled personnel;

●

any product liability or other lawsuits related to our products;

●

the extent to which we acquire or invest in businesses, products or technologies and other strategic relationships;

	●	the costs of financing unanticipated working capital requirements and responding to competitive pressures; and

	●	maintaining minimum shareholders’ equity requirements and complying with other continue listing standards under the NYSE American Company Guide; and

●

the impact of the COVID-19 outbreak and the Russian invasion of Ukraine, which may exacerbate the magnitude of the factors discussed above.

Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through payments received under our license agreements, debt or equity financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs or our commercialization efforts.

Research and Development, Patents and Licenses, Etc.

Our research and development expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory supplies and costs for facilities and equipment. We charge all research and development expenses to operations as they are incurred. We expect our research and development expense to remain our primary expense in the near future as we continue to develop our products. Increases or decreases in research and development expenditures are attributable to the number and/or duration of the pre-clinical and clinical studies that we conduct.

The following table identifies our current major research and development projects:

Project	Status	Expected or Recent Near Term Milestone
Piclidenoson	COMFORT Phase III study in psoriasis	Preparatory work for pivotal Phase III studies following meetings with FDA & EMA.

Namodenoson	Phase III in HCC	Enrolling patients
	Phase IIb study in SLD	Enrolling patients
	Phase IIa study in pancreatic cancer	Preparatory work for Phase IIa study

We record certain costs for each development project on a “direct cost” basis, as they are recorded to the project for which such costs are incurred. Such costs include, but are not limited to, CRO expenses, drug production for pre-clinical and clinical studies and other pre-clinical and clinical expenses. However, certain other costs, including but not limited to, salary expenses (including salaries for research and development personnel), facilities, depreciation, share-based compensation and other overhead costs are recorded on an “indirect cost” basis, i.e., they are shared among all of our projects and are not recorded to the project for which such costs are incurred. We do not allocate direct salaries to projects due to the fact that our project managers are generally involved in several projects at different stages of development, and the related salary expense is not significant to the overall cost of the applicable projects. In addition, indirect labor costs relating to our support of the research and development process, such as manufacturing, controls, pre-clinical analysis, laboratory testing and initial drug sample production, as well as rent and other administrative overhead costs, are shared by many different projects and have never been considered by management to be of significance in its decision-making process with respect to any specific project. Accordingly, such costs have not been specifically allocated to individual projects.

Set forth below is a summary of the gross direct costs allocated to our main projects on an individual basis, as well as the gross direct costs allocated to our less significant projects on an aggregate basis, for the years ended December 31, 2020, 2021 and 2022 and for the six months ended June 30, 2023 and on an aggregate basis since project inception:

	($ in thousands)						Six Months Ended		Costs Since
	Year Ended December 31,						June 30,		Project
	2020		2021		2022		2023		Inception

Piclidenoson		6,046		4,041		2,790		1,032		47,619
Namodenoson		1,261		3,991		3,383		1,665		21,075
CF602		-		31		6		-		1,740
Other projects		2,199		-		-		-		4,129
Total gross direct project costs ⁽¹⁾		9,506		8,063		6,179		2,697		74,563

(1)	Does not include indirect project costs and overhead, such as payroll and related expenses (including stock-based compensation), facilities, depreciation and impairment of intellectual property, which are included in total research and development expenses in our financial statements.

From our inception through June 30, 2023, we have incurred research and development expenses of approximately $143.61 million. We expect that a large percentage of our research and development expense in the future will be incurred in support of our current and future preclinical and clinical development projects. Due to the inherently unpredictable nature of preclinical and clinical development processes and given the early stage of our preclinical product development projects, we are unable to estimate with any certainty the costs we will incur in the continued development of the product candidates in our pipeline for potential commercialization. Clinical development timelines, the probability of success and development costs can differ materially from expectations. We expect to continue to test our product candidates in preclinical studies for toxicology, safety and efficacy, and to conduct additional clinical trials for each product candidate. If we are not able to enter into an out-licensing arrangement with respect to any product candidate prior to the commencement of later stage clinical trials, we may fund the trials for the product candidates ourselves.

While we are currently focused on advancing each of our product development projects, our future research and development expenses will depend on the clinical success of each product candidate, as well as ongoing assessments of each product candidate’s commercial potential. In addition, we cannot forecast with any degree of certainty which product candidates may be subject to future out-licensing arrangements, when such out-licensing arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for certain product candidates or projects in order to focus our resources on more promising product candidates or projects. Completion of clinical trials by us or our licensees may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.

The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:

●

the number of sites included in the clinical trials;

●

the length of time required to enroll suitable patients;

●

the number of patients that participate in the clinical trials;

●

the duration of patient follow-up;

●

the development stage of the product candidate; and

●

the efficacy and safety profile of the product candidate.

We expect our research and development expenses to increase in the future from current levels as we continue the advancement of our clinical trials and preclinical product development and to the extent we in-license new product candidates. The lengthy process of completing clinical trials and seeking regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not able to estimate with any certainty when we would recognize any net cash inflows from our projects.

Trend Information.

We are a development stage company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization efforts. As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause financial information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are identified in the preceding subsections.

Off-Balance Sheet Arrangements.

We have no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

EX-99.2 3 ea184381ex99-2_canfitebio.htm UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023

Exhibit 99.2

CAN-FITE BIOPHARMA LTD.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2023

UNAUDITED

IN U.S. DOLLARS

INDEX

		Page

Condensed Consolidated Balance Sheets		2 - 3

Condensed Consolidated Statements of Comprehensive Loss		4

Condensed Consolidated Statements of Changes in Equity		5

Condensed Consolidated Statements of Cash Flows		6 - 7

Notes to Condensed Consolidated Financial Statements		8 - 12

- - - - - - - - - - -

CAN-FITE BIOPHARMA LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

	June 30,		December 31,
	2023		2022
ASSETS

CURRENT ASSETS:

Cash and cash equivalents	$	3,458	$	2,978
Short term deposits		6,147		5,001
Prepaid expenses and other current assets		1,293		1,170
Short-term investment		11		8

Total current assets		10,909		9,157

NON-CURRENT ASSETS:

Operating lease right of use assets		87		84
Property, plant and equipment, net		36		42

Total non-current assets		123		126

Total assets	$	11,032	$	9,283

The accompanying notes are an integral part of the Condensed consolidated financial statements.

- 2 -

CAN-FITE BIOPHARMA LTD.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

	June 30,			December 31,
	2023			2022

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:

Trade payables	$	810		$	896
Current maturity of operating lease liability		44			48
Deferred revenues		783			783
Other accounts payable		596			775

Total current liabilities		2,233			2,502

NON-CURRENT LIABILITIES:

Long - term operating lease liability		22			14
Deferred revenues		1,903			2,295

Total long-term liabilities		1,925			2,309

CONTIGENT LIABILITIES AND COMMITMENTS

SHAREHOLDERS’ EQUITY:

Ordinary shares of no-par value - Authorized: 5,000,000,000 shares at June 30, 2023 and December 31, 2022; Issued and outstanding: 1,224,837,393 and 815,746,293 shares as of June 30, 2023 and December 31, 2022		-			-
Additional paid-in capital		160,814			154,192
Accumulated other comprehensive income		1,127			1,127
Accumulated deficit		(155,067	)		(150,847	)

Total equity		6,874			4,472

Total liabilities and shareholders’ equity	$	11,032		$	9,283

The accompanying notes are an integral part of the Condensed consolidated financial statements.

- 3 -

CAN-FITE BIOPHARMA LTD.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

	Six months ended June 30,
	2023			2022

Revenues	$	392		$	409

Research and development expenses		(3,417	)		(3,273	)
General and administrative expenses		(1,471	)		(1,576	)

Operating loss		(4,496	)		(4,440	)

Total financial income (expense), net		276			(185	)

Net loss		(4,220	)		(4,625	)

Basic and diluted net loss per share		(0.00	)		(0.00	)

Weighted average number of ordinary shares used in computing basic and diluted net loss per share		1,202,110,110			815,746,293

The accompanying notes are an integral part of the Condensed consolidated financial statements.

- 4 -

CAN-FITE BIOPHARMA LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

	Ordinary shares				Additional paid-in		Accumulated other comprehensive		Accumulated			Total
	Number		Amount		capital		income		deficit			equity

Balance as of January 1, 2023		815,746,293		-	$	154,192	$	1,127	$	(150,847	)	$	4,472

Net loss		-		-		-		-		(4,220	)		(4,220	)

Issuance of ordinary shares and warrants, net of issuance costs of $973		90,000,000		-		6,526		-		-			6,526

Issuance of ordinary shares due to exercise of warrants		319,091,100		-		1		-		-			1

Share-based compensation		-		-		95		-		-			95

Balance as of June 30, 2023		1,224,837,393	$	-	$	160,814	$	1,127	$	(155,067	)	$	6,874

	Ordinary shares				Additional paid-in		Accumulated other comprehensive		Accumulated			Total
	Number		Amount		capital		income		deficit			equity

Balance as of January 1, 2022		815,746,293	$	60,654	$	93,275	$	1,127	$	(140,674	)	$	14,382

Net loss		-		-		-		-		(4,625	)		(4,625	)

Share-based compensation		-		-		135		-		-			135

Balance as of June 30, 2022		815,746,293	$	60,654	$	93,410	$	1,127	$	(145,299	)	$	9,892

The accompanying notes are an integral part of the Condensed consolidated financial statements.

- 5 -

CAN-FITE BIOPHARMA LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

	Six months ended June 30,
	2023			2022

Cash flows from operating activities:

Net loss	$	(4,220	)	$	(4,625	)

Adjustments required to reconcile net loss to net cash used in operating activities:

Depreciation of property, plant and equipment		8			6
Reduction in the carrying amount of operating lease right of use asset		28			27
Share-based compensation		95			135
Changes in fair value of short-term investment		(3	)		198
Financial expenses (income), net		(146	)		92
Change in prepaid expenses, and other current assets		(123	)		(894	)
Decrease in operating lease liability		(27	)		(37	)
Decrease in trade payables		(86	)		(130	)
Decrease in deferred revenues		(392	)		(409	)
Decrease in other accounts payable		(179	)		(441	)

Net cash used in operating activities	$	(5,045	)	$	(6,078	)

The accompanying notes are an integral part of the Condensed consolidated financial statements.

- 6 -

CAN-FITE BIOPHARMA LTD.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

	Six months ended June 30,
	2023			2022

Cash flows from investing activities:
Purchase of property, plant and equipment		(2	)		(5	)
Maturity of short-term deposits		5,000			17,997
Investment in short-term deposits		(6,000	)		(14,500	)

Net cash provided by (used in) investing activities	$	(1,002	)	$	3,492

Cash flows from financing activities:

Proceeds from issuance of ordinary shares and warrants, net of issuance costs		6,526			-
Proceeds from issuance of ordinary share due to exercise of warrants		1			-

Net cash provided by financing activities	$	6,527		$	-

Exchange differences on balances of cash and cash equivalents		*	)		(92	)

Increase (decrease) in cash and cash equivalents		480			(2,678	)
Cash and cash equivalents at the beginning of the period		2,978			4,390

Cash and cash equivalents at the end of the period	$	3,458		$	1,712

Supplemental disclosures of noncash investing and financing activities:

Lease liabilities arising from obtaining right-of-use-assets	$	32			-

Represent an amount lower than 1 thousands.

The accompanying notes are an integral part of the Condensed consolidated financial statements.

- 7 -

CAN-FITE BIOPHARMA LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 1:-

GENERAL

Can-Fite Biopharma Ltd. (the “Company”) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, SLD and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company’s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.

The Company’s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol “CFBI” and the Company’s American Depositary Shares (“ADSs”) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company’s ADSs have been publicly traded on the NYSE American under the symbol “CANF”. Each ADS represents 300 ordinary shares of the Company.

During the six months ended June 30, 2023, the Company incurred net losses of USD 4,220 and it had negative cash flows from operating activities in the amount of USD 5,045.

Furthermore, the Company intends to continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities.

If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a cost reduction and may be required to delay part of its development programs. The Company’s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company’s products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.

NOTE 2:-

SIGNIFICANT ACCOUNTING POLICIES

The significant accounting policies that have been applied in the preparation of the unaudited consolidated Condensed financial statements are identical to those that were applied in preparation of the Company’s most recent annual financial statements for the year ended December 31, 2022 included in the Annual Report on Form 20-F.

NOTE 3:-

UNAUDITED CONDENSED FINANCIAL STATEMENTS

These unaudited condensed consolidated financial statements have been prepared as of June 30, 2023 and for the six months period then ended. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been omitted. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the accompanying notes of the Company for the year ended December 31, 2022 that are included in the Company’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 30, 2023 (the “Annual Report on Form 20-F”). The results of operations presented are not necessarily indicative of the results to be expected for the year ending December 31, 2023.

- 8 -

CAN-FITE BIOPHARMA LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 4:-

DEFERRED REVENUES

Contract liabilities include amounts received from customers for which revenue has not yet been recognized. Contract liabilities amounted to $2,686 and $3,078 as of June 30, 2023 and December 31, 2022, respectively and are presented under deferred revenues. During the six-month period ended June 30, 2023, the Company recognized revenues in the amount of $392 which have been included in the contract liabilities at December 31, 2022.

NOTE 5:-

FAIR VALUE MEASUREMENTS

In accordance with ASC 820 “Fair Value Measurements and Disclosures”, the Company measures its short-term investment at fair value. Short-term investments are classified within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets that the Company has the ability to access. The company’s short-term investment consists of an equity investment in a publicly traded company.

	June 30, 2023
	Fair value measurements
Description	Fair value		Level 1		Level 2		Level 3

Short-term equity investment	$	11	$	11	$	-	$	-

	December 31, 2022
	Fair value measurements
Description	Fair value		Level 1		Level 2		Level 3

Short-term equity investment	$	8	$	8	$	-	$	-

NOTE 6:-

EARNING PER SHARE

Basic and diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each period. Diluted net loss per share is calculated based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260, “Earnings per Share”.

- 9 -

CAN-FITE BIOPHARMA LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 6:-

EARNING PER SHARE (Cont.)

The following table sets forth the computation of basic and diluted net loss per share for the periods presented:

	Six month ended June 30,
	2023			2022

Numerator:
Net loss applicable to shareholders of ordinary shares	$	(4,220	)	$	(4,625	)

Denominator:
Weighted average shares used in computing basic and diluted net loss per share		1,202,110,110			815,746,293
Net loss per share of ordinary share, basic and diluted	$	(0.00	)	$	(0.00	)

All outstanding share options and warrants for the period ended June 30, 2023 and 2022 have been excluded from the calculation of the diluted net loss per share, because all such securities are anti-dilutive for all periods presented.

	Six month ended June 30, 2023		Six month ended June 30, 2022

Options		42,477,000		19,256,200

Warrants		1,222,016,340		377,947,640

Total		1,264,493,340		397,203,840

- 10 -

CAN-FITE BIOPHARMA LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 7:-

SHAREHOLDERS EQUITY

On January 11, 2023, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”), pursuant to which the Company agreed to sell and issue in a registered direct offering (the “Registered Direct Offering”) an aggregate of 90,000,000 ordinary shares for a purchase price of $0.018 per share (the “RD Shares”) and pre-funded warrants to purchase up to 210,000,000 of the Company’s ordinary shares at a purchase price of $0.018 per share and at an immaterial exercise price (the “Pre-funded Warrants”), and, unregistered Series A warrants to purchase up to 300,000,000 ordinary shares for an exercise price of $0.02 per shares (the “Series A Warrants”), and unregistered Series B warrants to purchase up to 300,000,000 ordinary shares for exercise price of $0.018 per share (the “Series B Warrants”).

In addition, the Company entered into a securities purchase agreement (the “PIPE Purchase Agreement,” and together with the RD Purchase Agreement, the “Purchase Agreements”) pursuant to which the Company agreed to sell and issue in a concurrent private placement (the “PIPE Offering,” and together with the Registered Direct Offering, the “Offerings”) unregistered Pre-funded Warrants to purchase up to 109,091,100 of the Company’ ordinary shares at purchase price of $0.018 per share and additional immaterial exercise price per share, unregistered Series A Warrants to purchase up to 109,091,100 of the Company’s ordinary shares for an exercise price of $0.02 per share and unregistered Series B Warrants to purchase up to 109,091,100 of the Company’s ordinary shares for an exercise price of $0.018 per share.

Moreover, the Company has also issued a placement agent warrants (the “Placement Agent Warrants”) on substantially the same terms as the Series A Warrants to purchase up to 28,636,500 of the Company’s ordinary shares for an exercise price of $0.022 per share.

As part of the aforementioned Offerings, the Company paid an aggregate amount of $973 issuance costs.

The Company received total consideration of $6,526 net of issuance costs from the above mentioned issuance of shares, prefunded warrants and Series A and B warrants.

The Company accounted for the aforementioned warrants as freestanding instrument classified at part of the Company’s permanent equity in accordance with ASC-480 and ASC-815.

The Company amended certain warrants to purchase up to an aggregate of 180,000,000 ordinary shares that were issued in December 2021 to the investor in this offering and private placement by reducing the exercise prices from $0.067 per share to $0.018 per share.

The Company accounted for the reduced in the warrants exercise price as issuance costs to be recorded in the Company’s additional paid in capital in accordance with ASC-815.

During the six months ended June 30, 2023, certain investors exercised pre-funded warrants and purchased 319,091,100 of the Company’s ordinary shares for an exercise price at an immaterial amount.

On May 1, 2023, the Company’s board of directors approved a grant of 15,500,000 unlisted options exercisable into 15,500,000 of the Company’s ordinary shares to the Company’s employees for an exercise price of NIS 0.026 per share and 40,000,000 unlisted options exercisable into 40,000,000 of the Company’s ordinary shares to the Company’s directors and chairman of the board of directors (subject to shareholders’ approval which was obtained on August 7, 2023, subsequent to balance sheet date) for an exercise price of NIS 0.026 per share.

The options will vest on a quarterly basis for a period of 4 years from the date of grant.

- 11 -

CAN-FITE BIOPHARMA LTD.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S dollars in thousands (except for share and per share data)

NOTE 7:-

SHAREHOLDERS EQUITY (Cont.)

In addition, the Company’s board of directors has also approved the increase of the options pool reserved under the Plan for issuance of ordinary share by 50,000,000 additional options to a total of 85,000,000. As of June 30, 2023, 42,523,000 options are available for a future grant.

	Number of options			Weighted average exercise price		Weighted average remaining contractual terms (in years)		Aggregate intrinsic value

Outstanding at December 31, 2022		27,002,200			0.13		7.14		-
Grants		15,500,000			0.01		-		-
Forfeited/expired		(25,200	)		4.05		-		-

Outstanding at June 30, 2023		42,477,000			0.08		7.83		-

Vested and expected to vest at June 30, 2023		42,477,000			0.08		7.83		-

Exercisable at June 30, 2023		14,217,625			0.17		6.61		-

- 12 -

EX-99.3 4 ea184381ex99-3_canfitebio.htm PRESS RELEASE DATED AUGUST 31, 2023

Exhibit 99.3

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

PETACH TIKVA, Israel, August 31, 2023 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the six months ended June 30, 2023.

Clinical Progress

Pivotal Phase III Advanced Liver Cancer Study—Can-Fite’s pivotal Phase III liver cancer study, Liveration, which continues enrollment is designed to assess Namodenoson in the treatment of patients with advanced hepatocellular carcinoma (HCC) and underlying Child Pugh B7 (CPB7) who have not responded to one or two other lines of therapy. The primary endpoint is overall survival. An interim analysis will be conducted by an Independent Data Monitoring Committee (IDMC) after 50% of the planned 450 patients are enrolled and treated.

Breakthrough Abstract Award–Can-Fite was recently granted a prestigious Breakthrough Abstract Award by the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation for the development of a novel approach to treat advanced liver cancer with the A3 adenosine receptor agonist, Namodenoson.

Exploratory Phase II Pancreatic Cancer Study—Can-Fite is preparing an open-label Phase II exploratory trial to assess the safety and efficacy of Namodenoson in the treatment of patients with pancreatic cancer who have received at least one previous systemic therapy. In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition. The mechanism of action entails de-regulation of the Wnt signal transduction pathway, a key modulator of pancreatic carcinoma cell growth.

ASCO Recognition—Can-Fite’s pancreatic cancer program received recognition from ASCO when its study titled “Effects of Namodenoson on Pancreatic Carcinoma: Preclinical Evidence” was published in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings.

Preparatory Work for Pivotal Phase III Psoriasis Study; Can Fite Received Green Light from FDA and EMA— Following positive responses from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its registration plan and pivotal Phase III study protocol for Piclidenoson in the treatment of moderate to severe psoriasis, the Company is preparing for study initiation. The FDA requested two Phase III studies and also encouraged the Company to enroll adolescent patients due to Piclidenoson’s strong safety profile demonstrated over its development history and prior clinical studies. Can-Fite has submitted to the FDA a pediatric plan to allow the registration of Piclidenoson for the treatment of adolescents. Inclusion of adolescents for the psoriasis Indication is expected to broaden the market.

Development for Treatment of Lowe Syndrome, a Rare Genetic Disease—Researchers at the University of Naples Federico II and The Telethon Institute of Genetics and Medicine (TIGEM) in Italy found Piclidenoson to be effective in pre-clinical studies for the treatment of Lowe Syndrome. Can-Fite and Fondazione Telethon signed an agreement outlining their collaboration for the development of Piclidenoson for the treatment Lowe Syndrome, a rare genetic disease with no treatment available, and an estimated $100 million treatment market in the U.S. alone.

“With two ongoing studies and two more about to commence in large treatment markets with unmet needs, we continue to advance our late-stage development pipeline to bring our potentially game-changing drugs to market,” stated Can-Fite CEO & CFO Motti Farbstein.

Dr. Pnina Fishman, Can-Fite’s CSO and Executive Chairman added, “We are particularly excited about our entry into the rare genetic disease field with the discovery of Piclidenoson’s efficacy in Lowe Syndrome in pre-clinical studies. Given Piclidenoson’s very favorable safety profile, we believe it will be a good candidate for directly entering advanced stage trials in children and adolescents living with Lowe Syndrome. Rare genetic diseases can have a more direct rapid path to regulatory approval with smaller trial sizes due to the pressing need in a small, unserved patient population.”

Financial Results

Net loss for the six months ended June 30, 2023 was $4.22 million compared with a net loss of $4.62 million for the six months ended June 30, 2022. The decrease in net loss for the six months ended June 30, 2023 was primarily attributable to the increase in finance income, net.

As of June 30, 2023, Can-Fite had cash and cash equivalents and short term deposits of $9.60 million as compared to $7.98 million at December 31, 2022. The decrease in cash during the six months ended June 30, 2023 is due to the ongoing operations of the Company.

The Company’s consolidated financial results for the six months ended June 30, 2023 are presented in accordance with US GAAP Reporting Standards.

CONSOLIDATED BALANCE SHEETS

U.S dollars in thousands (except for share and per share data)

	June 30,		December 31,
	2023		2022
	Unaudited

ASSETS

CURRENT ASSETS:

Cash and cash equivalents	$	3,458	$	2,978
Short term deposits		6,147		5,001
Prepaid expenses and other current assets		1,293		1,170
Short-term investment		11		8

Total current assets		10,909		9,157

NON-CURRENT ASSETS:

Operating lease right of use assets		87		84
Property, plant and equipment, net		36		42

Total non-current assets		123		126

Total assets	$	11,032	$	9,283

CONSOLIDATED BALANCE SHEETS

U.S dollars in thousands (except for share and per share data)

	June 30,			December 31,
	2023			2022
	Unaudited

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:

Trade payables	$	810		$	896
Current maturity of operating lease liability		44			48
Deferred revenues		783			783
Other accounts payable		596			775

Total current liabilities		2,233			2,502

NON-CURRENT LIABILITIES:

Long-term operating lease liability		22			14
Deferred revenues		1,903			2,295

Total long-term liabilities		1,925			2,309

CONTIGENT LIABILITIES AND COMMITMENTS

SHAREHOLDERS’ EQUITY:

Ordinary shares of no-par value - Authorized: 5,000,000,000 shares at June 30, 2023 and December 31, 2022; Issued and outstanding: 1,224,837,393 and 815,746,293 shares as of June 30, 2023 and December 31, 2022		-			-
Additional paid-in capital		160,814			154,192
Accumulated other comprehensive income		1,127			1,127
Accumulated deficit		(155,067	)		(150,847	)

Total equity		6,874			4,472

Total liabilities and shareholders’ equity	$	11,032		$	9,283

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

U.S dollars in thousands (except for share and per share data)

	Six months ended June 30,
	2023			2022
	Unaudited

Revenues	$	392		$	409

Research and development expenses		(3,417	)		(3,273	)
General and administrative expenses		(1,471	)		(1,576	)

Operating loss		(4,496	)		(4,440	)

Total financial income (expense), net		276			(185	)

Net loss		(4,220	)		(4,625	)

Basic and diluted net loss per share		(0.00	)		(0.00	)

Weighted average number of ordinary shares used in computing basic and diluted net loss per share		1,202,110,110			815,746,293

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis and is expected to commence a pivotal Phase III. Can-Fite’s cancer and liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of steatotic liver disease (SLD), a Phase III pivotal trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 30, 2023 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

Contact

Can-Fite BioPharma

Motti Farbstein

info@canfite.com

+972-3-9241114

EX-101.SCH 5 canf-20230630.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - General link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Unaudited Condensed Financial Statements link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Deferred Revenues link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Earning Per Share link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Shareholders Equity link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Earning Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Shareholders Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - General (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Deferred Revenues (Details) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Shareholders Equity (Details) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Shareholders Equity (Details) - Schedule of Share Options and Their Weighted Average Exercise Price link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 canf-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 canf-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 canf-20230630_lab.xml XBRL LABEL FILE Total current assets Total non-current assets Total assets Total current liabilities Total long-term liabilities Total equity Balance Balance Total liabilities and shareholders’ equity Operating loss Net loss Net loss Net losses Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net cash used in operating activities Net cash provided by (used in) investing activities Net cash provided by financing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period General [Abstract] Significant Accounting Policies [Abstract] Unaudited Condensed Financial Statements [Abstract] Deferred Revenues [Abstract] Fair Value Measurements [Abstract] Fair Value Hierarchy and NAV [Axis] Schedule of Computation of Basic and Diluted Net Loss Per Share [Abstract] Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Abstract] Shareholders Equity [Abstract] Schedule of Share Options and Their Weighted Average Exercise Price [Abstract] Number of options, Beginning Number of options, Ending Weighted average exercise price, Beginning Weighted average exercise price, Ending Document Type Document Fiscal Year Focus Entity File Number Entity Registrant Name Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Document Period End Date Entity Central Index Key ASSETS CURRENT ASSETS: Cash and cash equivalents Short term deposits Prepaid expenses and other current assets Short-term investment Short-term equity investment NON-CURRENT ASSETS: Operating lease right of use assets Property, plant and equipment, net LIABILITIES AND SHAREHOLDERS’ EQUITY CURRENT LIABILITIES: Trade payables Current maturity of operating lease liability Deferred revenues Other accounts payable NON-CURRENT LIABILITIES: Long - term operating lease liability Deferred revenues CONTIGENT LIABILITIES AND COMMITMENTS SHAREHOLDERS’ EQUITY: Ordinary shares of no-par value - Authorized: 5,000,000,000 shares at June 30, 2023 and December 31, 2022; Issued and outstanding: 1,224,837,393 and 815,746,293 shares as of June 30, 2023 and December 31, 2022 Ordinary shares par value (in Dollars per share) Ordinary shares authorized Ordinary shares issued Ordinary shares outstanding Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Revenues Total financial income (expense), net Basic net loss per share (in Dollars per share) Basic net loss per share Diluted net loss per share Weighted average number of ordinary shares used in computing basic net loss per share (in Shares) Weighted average number of ordinary shares used in computing basic net loss per share Weighted average number of ordinary shares used in computing diluted net loss per share Issuance of ordinary shares and warrants, net of issuance costs of $ 973 Issuance of ordinary shares and warrants, net of issuance costs of $ 973 (in Shares) Net of issuance costs Issuance of ordinary shares due to exercise of warrants Issuance of ordinary shares due to exercise of warrants (in Shares) Share-based compensation Cash flows from operating activities: Adjustments required to reconcile net loss to net cash used in operating activities: Depreciation of property, plant and equipment Reduction in the carrying amount of operating lease right of use asset Share-based compensation Financial expenses (income), net Decrease in operating lease liability Decrease in trade payables Decrease in deferred revenues Decrease in other accounts payable Cash flows from investing activities: Maturity of short-term deposits Cash flows from financing activities: Proceeds from issuance of ordinary shares and warrants, net of issuance costs Proceeds from issuance of ordinary share due to exercise of warrants Exchange differences on balances of cash and cash equivalents Supplemental disclosures of noncash investing and financing activities: Lease liabilities arising from obtaining right-of-use-assets Research and development expenses General and administrative expenses Changes in fair value of short-term investment Change in prepaid expenses, and other current assets Purchase of property, plant and equipment Investment in short-term deposits Ordinary shares Additional paid-in capital Accumulated other comprehensive income Accumulated deficit GENERAL SIGNIFICANT ACCOUNTING POLICIES UNAUDITED CONDENSED FINANCIAL STATEMENTS DEFERRED REVENUES FAIR VALUE MEASUREMENTS Schedule of Financial Assets and Liabilities Measured at Fair Value EARNING PER SHARE Schedule of Computation of Basic and Diluted Net Loss Per Share Numerator: Net loss applicable to shareholders of Ordinary Shares Denominator: Weighted average number of ordinary shares used in computing diluted net loss per share Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders Options Warrants Total SHAREHOLDERS EQUITY Schedule of Share Options and Their Weighted Average Exercise Price Weighted average remaining contractual terms, Beginning Aggregate intrinsic value, Beginning Aggregate intrinsic value, Ending Number of options, Grants Weighted average exercise price, Grants Weighted average exercise price, Forfeited/expired Weighted average remaining contractual terms, Ending Number of options, Vested and expected to vest Weighted average exercise price, Vested and expected to vest Weighted average remaining contractual terms, Vested and expected to vest Aggregate intrinsic value, Vested and expected to vest Number of options, Exercisable Weighted average exercise price, Exercisable Weighted average remaining contractual terms, Exercisable Aggregate intrinsic value, Exercisable EX-101.PRE 9 canf-20230630_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2023
Document Information Line Items
Entity Registrant Name	CAN-FITE BIOPHARMA LTD.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001536196
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity File Number	001-36203

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 3,458	$ 2,978
Short term deposits	6,147	5,001
Prepaid expenses and other current assets	1,293	1,170
Short-term investment	11	8
Total current assets	10,909	9,157
NON-CURRENT ASSETS:
Operating lease right of use assets	87	84
Property, plant and equipment, net	36	42
Total non-current assets	123	126
Total assets	11,032	9,283
CURRENT LIABILITIES:
Trade payables	810	896
Current maturity of operating lease liability	44	48
Deferred revenues	783	783
Other accounts payable	596	775
Total current liabilities	2,233	2,502
NON-CURRENT LIABILITIES:
Long - term operating lease liability	22	14
Deferred revenues	1,903	2,295
Total long-term liabilities	1,925	2,309
CONTIGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY:
Ordinary shares of no-par value - Authorized: 5,000,000,000 shares at June 30, 2023 and December 31, 2022; Issued and outstanding: 1,224,837,393 and 815,746,293 shares as of June 30, 2023 and December 31, 2022
Additional paid-in capital	160,814	154,192
Accumulated other comprehensive income	1,127	1,127
Accumulated deficit	(155,067)	(150,847)
Total equity	6,874	4,472
Total liabilities and shareholders’ equity	$ 11,032	$ 9,283

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Ordinary shares par value (in Dollars per share)
Ordinary shares authorized	5,000,000,000	5,000,000,000
Ordinary shares issued	1,224,837,393	815,746,293
Ordinary shares outstanding	1,224,837,393	815,746,293

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Revenues	$ 392	$ 409
Research and development expenses	(3,417)	(3,273)
General and administrative expenses	(1,471)	(1,576)
Operating loss	(4,496)	(4,440)
Total financial income (expense), net	276	(185)
Net loss	$ (4,220)	$ (4,625)
Basic net loss per share (in Dollars per share)	$ 0	$ 0
Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)	1,202,110,110	815,746,293

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

+ Details

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Diluted net loss per share	$ 0.00	$ 0.00
Weighted average number of ordinary shares used in computing diluted net loss per share	1,202,110,110	815,746,293

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Equity (Unaudited) - USD ($) $ in Thousands	Ordinary shares	Additional paid-in capital	Accumulated other comprehensive income	Accumulated deficit	Total
Balance at Dec. 31, 2021	$ 60,654	$ 93,275	$ 1,127	$ (140,674)	$ 14,382
Balance (in Shares) at Dec. 31, 2021	815,746,293
Net loss				(4,625)	(4,625)
Share-based compensation		135			135
Balance at Jun. 30, 2022	$ 60,654	93,410	1,127	(145,299)	9,892
Balance (in Shares) at Jun. 30, 2022	815,746,293
Balance at Dec. 31, 2022		154,192	1,127	(150,847)	4,472
Balance (in Shares) at Dec. 31, 2022	815,746,293
Net loss				(4,220)	(4,220)
Issuance of ordinary shares and warrants, net of issuance costs of $ 973		6,526			6,526
Issuance of ordinary shares and warrants, net of issuance costs of $ 973 (in Shares)	90,000,000
Issuance of ordinary shares due to exercise of warrants		1			1
Issuance of ordinary shares due to exercise of warrants (in Shares)	319,091,100
Share-based compensation		95			95
Balance at Jun. 30, 2023		$ 160,814	$ 1,127	$ (155,067)	$ 6,874
Balance (in Shares) at Jun. 30, 2023	1,224,837,393

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 16 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parentheticals) $ in Thousands	Jun. 30, 2023 USD ($)
Statement of Stockholders' Equity [Abstract]
Net of issuance costs	$ 973

XML 17 R8.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands

6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Cash flows from operating activities:

Net loss

$ (4,220)

$ (4,625)

Adjustments required to reconcile net loss to net cash used in operating activities:

Depreciation of property, plant and equipment

Reduction in the carrying amount of operating lease right of use asset

Share-based compensation

135

Changes in fair value of short-term investment

(3)

198

Financial expenses (income), net

(146)

Change in prepaid expenses, and other current assets

(123)

(894)

Decrease in operating lease liability

(27)

(37)

Decrease in trade payables

(86)

(130)

Decrease in deferred revenues

(392)

(409)

Decrease in other accounts payable

(179)

(441)

Net cash used in operating activities

(5,045)

(6,078)

Cash flows from investing activities:

Purchase of property, plant and equipment

(2)

(5)

Maturity of short-term deposits

5,000

17,997

Investment in short-term deposits

(6,000)

(14,500)

Net cash provided by (used in) investing activities

(1,002)

3,492

Cash flows from financing activities:

Proceeds from issuance of ordinary shares and warrants, net of issuance costs

6,526

Proceeds from issuance of ordinary share due to exercise of warrants

Net cash provided by financing activities

6,527

Exchange differences on balances of cash and cash equivalents

^[1]

(92)

Increase (decrease) in cash and cash equivalents

480

(2,678)

Cash and cash equivalents at the beginning of the period

2,978

4,390

Cash and cash equivalents at the end of the period

3,458

1,712

Supplemental disclosures of noncash investing and financing activities:

Lease liabilities arising from obtaining right-of-use-assets

$ 32

[1]	Represent an amount lower than 1 thousands.

XML 18 R9.htm IDEA: XBRL DOCUMENT

General

6 Months Ended

Jun. 30, 2023

General [Abstract]

GENERAL

NOTE 1:-

GENERAL

During the six months ended June 30, 2023, the Company incurred net losses of USD 4,220 and it had negative cash flows from operating activities in the amount of USD 5,045.

XML 19 R10.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:-

SIGNIFICANT ACCOUNTING POLICIES

XML 20 R11.htm IDEA: XBRL DOCUMENT

Unaudited Condensed Financial Statements

6 Months Ended

Jun. 30, 2023

Unaudited Condensed Financial Statements [Abstract]

UNAUDITED CONDENSED FINANCIAL STATEMENTS

NOTE 3:-

UNAUDITED CONDENSED FINANCIAL STATEMENTS

XML 21 R12.htm IDEA: XBRL DOCUMENT

Deferred Revenues

6 Months Ended

Jun. 30, 2023

Deferred Revenues [Abstract]

DEFERRED REVENUES

NOTE 4:-

DEFERRED REVENUES

XML 22 R13.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2023

Fair Value Measurements [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 5:-

FAIR VALUE MEASUREMENTS

	June 30, 2023
	Fair value measurements
Description	Fair value		Level 1		Level 2		Level 3

Short-term equity investment	$	11	$	11	$	-	$	-

	December 31, 2022
	Fair value measurements
Description	Fair value		Level 1		Level 2		Level 3

Short-term equity investment	$	8	$	8	$	-	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R14.htm IDEA: XBRL DOCUMENT

Earning Per Share

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

EARNING PER SHARE

NOTE 6:-

EARNING PER SHARE

The following table sets forth the computation of basic and diluted net loss per share for the periods presented:

	Six month ended June 30,
	2023			2022

Numerator:
Net loss applicable to shareholders of ordinary shares	$	(4,220	)	$	(4,625	)

Denominator:
Weighted average shares used in computing basic and diluted net loss per share		1,202,110,110			815,746,293
Net loss per share of ordinary share, basic and diluted	$	(0.00	)	$	(0.00	)

	Six month ended June 30, 2023		Six month ended June 30, 2022

Options		42,477,000		19,256,200

Warrants		1,222,016,340		377,947,640

Total		1,264,493,340		397,203,840

XML 24 R15.htm IDEA: XBRL DOCUMENT

Shareholders Equity

6 Months Ended

Jun. 30, 2023

Shareholders Equity [Abstract]

SHAREHOLDERS EQUITY

NOTE 7:-

SHAREHOLDERS EQUITY

As part of the aforementioned Offerings, the Company paid an aggregate amount of $973 issuance costs.

The Company received total consideration of $6,526 net of issuance costs from the above mentioned issuance of shares, prefunded warrants and Series A and B warrants.

The Company accounted for the aforementioned warrants as freestanding instrument classified at part of the Company’s permanent equity in accordance with ASC-480 and ASC-815.

The Company accounted for the reduced in the warrants exercise price as issuance costs to be recorded in the Company’s additional paid in capital in accordance with ASC-815.

During the six months ended June 30, 2023, certain investors exercised pre-funded warrants and purchased 319,091,100 of the Company’s ordinary shares for an exercise price at an immaterial amount.

The options will vest on a quarterly basis for a period of 4 years from the date of grant.

	Number of options			Weighted average exercise price		Weighted average remaining contractual terms (in years)		Aggregate intrinsic value

Outstanding at December 31, 2022		27,002,200			0.13		7.14		-
Grants		15,500,000			0.01		-		-
Forfeited/expired		(25,200	)		4.05		-		-

Outstanding at June 30, 2023		42,477,000			0.08		7.83		-

Vested and expected to vest at June 30, 2023		42,477,000			0.08		7.83		-

Exercisable at June 30, 2023		14,217,625			0.17		6.61		-

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 25 R16.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2023

Fair Value Measurements [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value

	June 30, 2023
	Fair value measurements
Description	Fair value		Level 1		Level 2		Level 3

Short-term equity investment	$	11	$	11	$	-	$	-

	December 31, 2022
	Fair value measurements
Description	Fair value		Level 1		Level 2		Level 3

Short-term equity investment	$	8	$	8	$	-	$	-

XML 26 R17.htm IDEA: XBRL DOCUMENT

Earning Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Earnings Per Share [Abstract]

Schedule of Computation of Basic and Diluted Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share for the periods presented:

	Six month ended June 30,
	2023			2022

Numerator:
Net loss applicable to shareholders of ordinary shares	$	(4,220	)	$	(4,625	)

Denominator:
Weighted average shares used in computing basic and diluted net loss per share		1,202,110,110			815,746,293
Net loss per share of ordinary share, basic and diluted	$	(0.00	)	$	(0.00	)

Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders

	Six month ended June 30, 2023		Six month ended June 30, 2022

Options		42,477,000		19,256,200

Warrants		1,222,016,340		377,947,640

Total		1,264,493,340		397,203,840

XML 27 R18.htm IDEA: XBRL DOCUMENT

Shareholders Equity (Tables)

6 Months Ended

Jun. 30, 2023

Shareholders Equity [Abstract]

Schedule of Share Options and Their Weighted Average Exercise Price

	Number of options			Weighted average exercise price		Weighted average remaining contractual terms (in years)		Aggregate intrinsic value

Outstanding at December 31, 2022		27,002,200			0.13		7.14		-
Grants		15,500,000			0.01		-		-
Forfeited/expired		(25,200	)		4.05		-		-

Outstanding at June 30, 2023		42,477,000			0.08		7.83		-

Vested and expected to vest at June 30, 2023		42,477,000			0.08		7.83		-

Exercisable at June 30, 2023		14,217,625			0.17		6.61		-

XML 28 R19.htm IDEA: XBRL DOCUMENT

General (Details) - USD ($) $ in Thousands	6 Months Ended
General (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Jun. 30, 2022
General [Abstract]
Number of ordinary shares in each ADS (in Shares)	300
Net losses	$ (4,220)	$ (4,625)
Cash flows from operating activities	$ 5,045

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 29 R20.htm IDEA: XBRL DOCUMENT

Deferred Revenues (Details) - USD ($) $ in Thousands	6 Months Ended
Deferred Revenues (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Deferred Revenues [Abstract]
Contract liabilities	$ 2,686	$ 3,078
Recognized revenues	$ 392

XML 30 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Fair value [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value [Line Items]
Short-term equity investment	$ 11	$ 8
Level 1 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value [Line Items]
Short-term equity investment	11	8
Level 2 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value [Line Items]
Short-term equity investment
Level 3 [Member]
Schedule of Financial Assets and Liabilities Measured at Fair Value [Line Items]
Short-term equity investment

XML 31 R22.htm IDEA: XBRL DOCUMENT

Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Numerator:
Net loss applicable to shareholders of Ordinary Shares	$ (4,220)	$ (4,625)
Denominator:
Weighted average number of ordinary shares used in computing basic net loss per share	1,202,110,110	815,746,293
Basic net loss per share	$ 0	$ 0

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-11

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

+ Details

XML 32 R23.htm IDEA: XBRL DOCUMENT

Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share (Parentheticals) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Schedule of Computation of Basic and Diluted Net Loss Per Share [Abstract]
Weighted average number of ordinary shares used in computing diluted net loss per share	1,202,110,110	815,746,293
Diluted net loss per share	$ 0.00	$ 0.00

- Definition

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

XML 33 R24.htm IDEA: XBRL DOCUMENT

Earning Per Share (Details) - Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders - shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,264,493,340	397,203,840
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Options	42,477,000	19,256,200
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants	1,222,016,340	377,947,640

XML 34 R25.htm IDEA: XBRL DOCUMENT

Shareholders Equity (Details) $ / shares in Units, $ in Thousands				6 Months Ended
	Aug. 07, 2023 ₪ / shares	May 01, 2023 ₪ / shares shares	Jan. 11, 2023 $ / shares shares	Jun. 30, 2023 USD ($) $ / shares shares
Shareholders Equity (Details) [Line Items]
Aggregate ordinary shares			90,000,000	180,000,000
Exercise price \| (per share)	₪ 0.026	₪ 0.026		$ 0.018
Purchase of warrant				109,091,100
Warrant exercise price (in Dollars per share) \| $ / shares				$ 0.022
Placement agent warrants				28,636,500
Issuance costs (in Dollars) \| $				$ 973
Exercised pre-funded warrants				319,091,100
Unlisted options exercisable price		15,500,000
Exercisable ordinary shares		40,000,000
Period of grant				4 years
Issuance of ordinary share				85,000,000
Future grant shares				42,523,000
Pre-funded Warrants [Member]
Shareholders Equity (Details) [Line Items]
Aggregate ordinary shares			210,000,000
Exercise price \| $ / shares			$ 0.018
Series A [Member]
Shareholders Equity (Details) [Line Items]
Purchase of warrant			300,000,000	109,091,100
Warrant exercise price (in Dollars per share) \| $ / shares			$ 0.02	$ 0.02
Issuance costs (in Dollars) \| $				$ 6,526
Series B [Member]
Shareholders Equity (Details) [Line Items]
Purchase of warrant			300,000,000	109,091,100
Warrant exercise price (in Dollars per share) \| $ / shares			$ 0.018	$ 0.018
Issuance costs (in Dollars) \| $				$ 6,526
Maximum [Member]
Shareholders Equity (Details) [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares				$ 0.067
Minimum [Member]
Shareholders Equity (Details) [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares				$ 0.018
RD Shares [Member]
Shareholders Equity (Details) [Line Items]
Purchase price (in Dollars per share) \| $ / shares			$ 0.018
Board of Directors Chairman [Member]
Shareholders Equity (Details) [Line Items]
Unlisted options exercisable price		15,500,000
Exercisable ordinary shares		40,000,000
Issuance of ordinary share				50,000,000

XML 35 R26.htm IDEA: XBRL DOCUMENT

Shareholders Equity (Details) - Schedule of Share Options and Their Weighted Average Exercise Price	6 Months Ended
	Jun. 30, 2023 USD ($) $ / shares shares
Schedule of Share Options and Their Weighted Average Exercise Price [Abstract]
Number of options, Beginning \| shares	27,002,200
Weighted average exercise price, Beginning \| $ / shares	$ 0.13
Weighted average remaining contractual terms, Beginning	7 years 1 month 20 days
Aggregate intrinsic value, Beginning \| $
Number of options, Grants \| shares	15,500,000
Weighted average exercise price, Grants \| $ / shares	$ 0.01
Number of options, Forfeited/expired \| shares	(25,200)
Weighted average exercise price, Forfeited/expired \| $ / shares	$ 4.05
Number of options, Ending \| shares	42,477,000
Weighted average exercise price, Ending \| $ / shares	$ 0.08
Weighted average remaining contractual terms, Ending	7 years 9 months 29 days
Aggregate intrinsic value, Ending \| $
Number of options, Vested and expected to vest \| shares	42,477,000
Weighted average exercise price, Vested and expected to vest \| $ / shares	$ 0.08
Weighted average remaining contractual terms, Vested and expected to vest	7 years 9 months 29 days
Aggregate intrinsic value, Vested and expected to vest \| $
Number of options, Exercisable \| shares	14,217,625
Weighted average exercise price, Exercisable \| $ / shares	$ 0.17
Weighted average remaining contractual terms, Exercisable	6 years 7 months 9 days
Aggregate intrinsic value, Exercisable \| $

XML 36 ea184381-6k_canfitebio_htm.xml IDEA: XBRL DOCUMENT 0001536196 2023-01-01 2023-06-30 0001536196 2023-06-30 0001536196 2022-12-31 0001536196 2022-01-01 2022-06-30 0001536196 us-gaap:CommonStockMember 2022-12-31 0001536196 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001536196 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001536196 us-gaap:RetainedEarningsMember 2022-12-31 0001536196 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001536196 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001536196 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001536196 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001536196 us-gaap:CommonStockMember 2023-06-30 0001536196 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001536196 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001536196 us-gaap:RetainedEarningsMember 2023-06-30 0001536196 us-gaap:CommonStockMember 2021-12-31 0001536196 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001536196 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001536196 us-gaap:RetainedEarningsMember 2021-12-31 0001536196 2021-12-31 0001536196 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001536196 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001536196 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001536196 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001536196 us-gaap:CommonStockMember 2022-06-30 0001536196 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001536196 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001536196 us-gaap:RetainedEarningsMember 2022-06-30 0001536196 2022-06-30 0001536196 us-gaap:FairValueInputsLevel12And3Member 2023-06-30 0001536196 us-gaap:FairValueInputsLevel1Member 2023-06-30 0001536196 us-gaap:FairValueInputsLevel2Member 2023-06-30 0001536196 us-gaap:FairValueInputsLevel3Member 2023-06-30 0001536196 us-gaap:FairValueInputsLevel12And3Member 2022-12-31 0001536196 us-gaap:FairValueInputsLevel1Member 2022-12-31 0001536196 us-gaap:FairValueInputsLevel2Member 2022-12-31 0001536196 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001536196 canf:OptionsMember 2023-01-01 2023-06-30 0001536196 canf:OptionsMember 2022-01-01 2022-06-30 0001536196 canf:WarrantsMember 2023-01-01 2023-06-30 0001536196 canf:WarrantsMember 2022-01-01 2022-06-30 0001536196 2023-01-11 2023-01-11 0001536196 canf:RDSharesMember 2023-01-11 0001536196 canf:PrefundedWarrantsMember 2023-01-11 2023-01-11 0001536196 us-gaap:SeriesAMember 2023-01-11 0001536196 us-gaap:SeriesAMember 2023-01-11 2023-01-11 0001536196 us-gaap:SeriesBMember 2023-01-11 0001536196 us-gaap:SeriesBMember 2023-01-11 2023-01-11 0001536196 us-gaap:SeriesAMember 2023-06-30 0001536196 us-gaap:SeriesAMember 2023-01-01 2023-06-30 0001536196 us-gaap:SeriesBMember 2023-06-30 0001536196 us-gaap:SeriesBMember 2023-01-01 2023-06-30 0001536196 srt:MaximumMember 2023-01-01 2023-06-30 0001536196 srt:MinimumMember 2023-01-01 2023-06-30 0001536196 srt:BoardOfDirectorsChairmanMember 2023-05-01 0001536196 2023-05-01 0001536196 2023-05-01 2023-05-01 0001536196 2023-08-07 2023-08-07 0001536196 srt:BoardOfDirectorsChairmanMember 2023-06-30 iso4217:USD iso4217:USD shares shares iso4217:ILS shares 6-K 2023 001-36203 CAN-FITE BIOPHARMA LTD.

3458000

2978000

6147000

5001000

1293000

1170000

11000

8000

10909000

9157000

87000

84000

36000

42000

123000

126000

11032000

9283000

810000

896000

44000

48000

783000

596000

775000

2233000

2502000

22000

14000

1903000

2295000

1925000

2309000

5000000000

1224837393

815746293

160814000

154192000

1127000

-155067000

-150847000

6874000

4472000

11032000

9283000

392000

409000

3417000

3273000

1471000

1576000

-4496000

-4440000

276000

-185000

-4220000

-4625000

1202110110

815746293

154192000

1127000

-150847000

4472000

-4220000

973000

90000000

6526000

319091100

1000

95000

1224837393

160814000

1127000

-155067000

6874000

815746293

60654000

93275000

1127000

-140674000

14382000

-4625000

135000

815746293

60654000

93410000

1127000

-145299000

9892000

-4220000

-4625000

8000

6000

28000

27000

95000

135000

3000 -198000

-146000

92000

123000

894000

-27000

-37000

-86000

-130000

-392000

-409000

-179000

-441000

-5045000

-6078000

2000

5000

5000000

17997000

6000000

14500000

-1002000

3492000

6526000

1000

6527000

-92000

480000

-2678000

2978000

4390000

3458000

1712000

32000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 67px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GENERAL</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 67px"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Can-Fite Biopharma Ltd. (the “Company”) was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, SLD and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. The Company’s pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators at the A3AR.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s ordinary shares have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol “CFBI” and the Company’s American Depositary Shares (“ADSs”) began public trading on the over the counter market in the U.S. in October 2012 and since November 2013 the Company’s ADSs have been publicly traded on the NYSE American under the symbol “CANF”. Each ADS represents 300 ordinary shares of the Company.</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the six months ended June 30, 2023, the Company incurred net losses of USD 4,220 and it had negative cash flows from operating activities in the amount of USD 5,045.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, the Company intends to continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a cost reduction and may be required to delay part of its development programs. The Company’s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company’s products for at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p></td></tr> </table>

300

-4220000

5045000

2686000

3078000

392000

The Company’s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates: instruments as of the following dates:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"></td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">11</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">11</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"></td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; padding-bottom: 4pt">Short-term equity investment</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">8</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right">8</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 4pt double; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> </table>

11000

8000

The following table sets forth the computation of basic and diluted net loss per share for the periods presented:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six month ended <br/> June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"><b> </b></td><td style="padding-bottom: 1.5pt"><b> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"><b> </b></td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss applicable to shareholders of ordinary shares</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,220</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,625</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -9pt; padding-left: 9pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-40; -sec-ix-hidden: hidden-fact-39">Weighted average shares used in computing basic and diluted net loss per share</div></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,202,110,110</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">815,746,293</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-42; -sec-ix-hidden: hidden-fact-41">Net loss per share of ordinary share, basic and diluted</div></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.00</td><td style="text-align: left">)</td></tr> </table>

-4220

-4625

1202110110

815746293

The potential shares of ordinary shares that were excluded from the computation of diluted net loss per share attributable to ordinary shareholders for the periods presented because including them would have been anti-dilutive are as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six month ended<br/> June 30,<br/> 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six month ended<br/> June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-indent: -9pt; padding-left: 9pt">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">42,477,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">19,256,200</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,222,016,340</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">377,947,640</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -9pt; padding-left: 9pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">1,264,493,340</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">397,203,840</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

42477000

19256200

1222016340

377947640

1264493340

397203840

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 67px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7:-</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SHAREHOLDERS EQUITY</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"> <td style="width: 67px"></td><td style="width: 0.25in">1.</td><td style="text-align: justify"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On January 11, 2023, the Company entered into a securities purchase agreement (the “RD Purchase Agreement”), pursuant to which the Company agreed to sell and issue in a registered direct offering (the “Registered Direct Offering”) an aggregate of 90,000,000 ordinary shares for a purchase price of $0.018 per share (the “RD Shares”) and pre-funded warrants to purchase up to 210,000,000 of the Company’s ordinary shares at a purchase price of $0.018 per share and at an immaterial exercise price (the “Pre-funded Warrants”), and, unregistered Series A warrants to purchase up to 300,000,000 ordinary shares for an exercise price of $0.02 per shares (the “Series A Warrants”), and unregistered Series B warrants to purchase up to 300,000,000 ordinary shares for exercise price of $0.018 per share (the “Series B Warrants”).</p></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">In addition, the Company entered into a securities purchase agreement (the “PIPE Purchase Agreement,” and together with the RD Purchase Agreement, the “Purchase Agreements”) pursuant to which the Company agreed to sell and issue in a concurrent private placement (the “PIPE Offering,” and together with the Registered Direct Offering, the “Offerings”) unregistered Pre-funded Warrants to purchase up to 109,091,100 of the Company’ ordinary shares at purchase price of $0.018 per share and additional immaterial exercise price per share, unregistered Series A Warrants to purchase up to 109,091,100 of the Company’s ordinary shares for an exercise price of $0.02 per share and unregistered Series B Warrants to purchase up to 109,091,100 of the Company’s ordinary shares for an exercise price of $0.018 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">Moreover, the Company has also issued a placement agent warrants (the “Placement Agent Warrants”) on substantially the same terms as the Series A Warrants to purchase up to 28,636,500 of the Company’s ordinary shares for an exercise price of $0.022 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">As part of the aforementioned Offerings, the Company paid an aggregate amount of $973 issuance costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">The Company received total consideration of $6,526 net of issuance costs from the above mentioned issuance of shares, prefunded warrants and Series A and B warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">The Company accounted for the aforementioned warrants as freestanding instrument classified at part of the Company’s permanent equity in accordance with ASC-480 and ASC-815.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"> <td style="width: 67px"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">The Company amended certain warrants to purchase up to an aggregate of 180,000,000 ordinary shares that were issued in December 2021 to the investor in this offering and private placement by reducing the exercise prices from $0.067 per share to $0.018 per share.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">The Company accounted for the reduced in the warrants exercise price as issuance costs to be recorded in the Company’s additional paid in capital in accordance with ASC-815.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"> <td style="width: 67px"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">During the six months ended June 30, 2023, certain investors exercised pre-funded warrants and purchased 319,091,100 of the Company’s ordinary shares for an exercise price at an immaterial amount.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">On May 1, 2023, the Company’s board of directors approved a grant of 15,500,000 unlisted options exercisable into 15,500,000 of the Company’s ordinary shares to the Company’s employees for an exercise price of NIS 0.026 per share and 40,000,000 unlisted options exercisable into 40,000,000 of the Company’s ordinary shares to the Company’s directors and chairman of the board of directors (subject to shareholders’ approval which was obtained on August 7, 2023, subsequent to balance sheet date) for an exercise price of NIS 0.026 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">The options will vest on a quarterly basis for a period of 4 years from the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">In addition, the Company’s board of directors has also approved the increase of the options pool reserved under the Plan for issuance of ordinary share by 50,000,000 additional options to a total of 85,000,000. As of June 30, 2023, 42,523,000 options are available for a future grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 91px; text-align: justify">The following table lists the number of share options and their weighted average exercise prices in option plans of employees, directors and consultants for the six months period ended June 30, 2023 and related information: </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> remaining<br/> contractual<br/> terms <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">27,002,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.14</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"> -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Grants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">42,477,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.83</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">42,477,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.83</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">14,217,625</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.17</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6.61</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

90000000

0.018

210000000

0.018

300000000

0.02

300000000

0.018

109091100

0.018

109091100

0.02

109091100

0.018

28636500

0.022

973000

6526000

180000000

0.067

0.018

319091100

15500000

0.026

40000000

P4Y

50000000

85000000

42523000

The following table lists the number of share options and their weighted average exercise prices in option plans of employees, directors and consultants for the six months period ended June 30, 2023 and related information:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/> average <br/> exercise <br/> price</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted<br/> average<br/> remaining<br/> contractual<br/> terms <br/> (in years)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate<br/> intrinsic<br/> value</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: justify">Outstanding at December 31, 2022</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">27,002,200</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">0.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">7.14</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43"> -</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Grants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.01</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,200</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.05</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Outstanding at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">42,477,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.83</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Vested and expected to vest at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">42,477,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.08</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">7.83</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 4pt">Exercisable at June 30, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">14,217,625</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">0.17</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">6.61</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

27002200

0.13

P7Y1M20D

15500000

0.01

25200

4.05

42477000

0.08

P7Y9M29D

42477000

0.08

P7Y9M29D

14217625

0.17

P6Y7M9D

0.00

1202110110

815746293

1202110110

815746293

0.00

false --12-31 Q2 2023-06-30 0001536196 Represent an amount lower than 1 thousands.

EXCEL 37 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 38 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 39 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 40 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 60 127 1 true 17 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.canfite.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.canfite.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Sheet http://www.canfite.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.canfite.com/role/ConsolidatedIncomeStatement Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) Sheet http://www.canfite.com/role/ConsolidatedIncomeStatement_Parentheticals Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) Sheet http://www.canfite.com/role/ShareholdersEquityType2or3 Condensed Consolidated Statements of Changes in Equity (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parentheticals) Sheet http://www.canfite.com/role/ShareholdersEquityType2or3_Parentheticals Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.canfite.com/role/ConsolidatedCashFlow Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 8 false false R9.htm 008 - Disclosure - General Sheet http://www.canfite.com/role/General General Notes 9 false false R10.htm 009 - Disclosure - Significant Accounting Policies Sheet http://www.canfite.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Unaudited Condensed Financial Statements Sheet http://www.canfite.com/role/UnauditedCondensedFinancialStatements Unaudited Condensed Financial Statements Notes 11 false false R12.htm 011 - Disclosure - Deferred Revenues Sheet http://www.canfite.com/role/DeferredRevenues Deferred Revenues Notes 12 false false R13.htm 012 - Disclosure - Fair Value Measurements Sheet http://www.canfite.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 013 - Disclosure - Earning Per Share Sheet http://www.canfite.com/role/EarningPerShare Earning Per Share Notes 14 false false R15.htm 014 - Disclosure - Shareholders Equity Sheet http://www.canfite.com/role/ShareholdersEquity Shareholders Equity Notes 15 false false R16.htm 015 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.canfite.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.canfite.com/role/FairValueMeasurements 16 false false R17.htm 016 - Disclosure - Earning Per Share (Tables) Sheet http://www.canfite.com/role/EarningPerShareTables Earning Per Share (Tables) Tables http://www.canfite.com/role/EarningPerShare 17 false false R18.htm 017 - Disclosure - Shareholders Equity (Tables) Sheet http://www.canfite.com/role/ShareholdersEquityTables Shareholders Equity (Tables) Tables http://www.canfite.com/role/ShareholdersEquity 18 false false R19.htm 018 - Disclosure - General (Details) Sheet http://www.canfite.com/role/GeneralDetails General (Details) Details http://www.canfite.com/role/General 19 false false R20.htm 019 - Disclosure - Deferred Revenues (Details) Sheet http://www.canfite.com/role/DeferredRevenuesDetails Deferred Revenues (Details) Details http://www.canfite.com/role/DeferredRevenues 20 false false R21.htm 020 - Disclosure - Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value Sheet http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value Details http://www.canfite.com/role/FairValueMeasurementsTables 21 false false R22.htm 021 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share Sheet http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share Details http://www.canfite.com/role/EarningPerShareTables 22 false false R23.htm 022 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share (Parentheticals) Sheet http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable_Parentheticals Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share (Parentheticals) Details http://www.canfite.com/role/EarningPerShareTables 23 false false R24.htm 023 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders Sheet http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable Earning Per Share (Details) - Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders Details http://www.canfite.com/role/EarningPerShareTables 24 false false R25.htm 024 - Disclosure - Shareholders Equity (Details) Sheet http://www.canfite.com/role/ShareholdersEquityDetails Shareholders Equity (Details) Details http://www.canfite.com/role/ShareholdersEquityTables 25 false false R26.htm 025 - Disclosure - Shareholders Equity (Details) - Schedule of Share Options and Their Weighted Average Exercise Price Sheet http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable Shareholders Equity (Details) - Schedule of Share Options and Their Weighted Average Exercise Price Details http://www.canfite.com/role/ShareholdersEquityTables 26 false false All Reports Book All Reports ea184381-6k_canfitebio.htm ea184381ex99-2_canfitebio.htm canf-20230630.xsd canf-20230630_cal.xml canf-20230630_def.xml canf-20230630_lab.xml canf-20230630_pre.xml ea184381ex99-1_canfitebio.htm ea184381ex99-3_canfitebio.htm http://fasb.org/srt/2023 http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 43 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea184381-6k_canfitebio.htm ea184381ex99-2_canfitebio.htm": { "axisCustom": 0, "axisStandard": 6, "baseTaxonomies": { "http://fasb.org/srt/2023": 1, "http://fasb.org/us-gaap/2023": 268, "http://xbrl.sec.gov/dei/2023": 9 }, "contextCount": 60, "dts": { "calculationLink": { "local": [ "canf-20230630_cal.xml" ] }, "definitionLink": { "local": [ "canf-20230630_def.xml" ] }, "inline": { "local": [ "ea184381-6k_canfitebio.htm", "ea184381ex99-2_canfitebio.htm" ] }, "labelLink": { "local": [ "canf-20230630_lab.xml" ] }, "presentationLink": { "local": [ "canf-20230630_pre.xml" ] }, "schema": { "local": [ "canf-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] } }, "elementCount": 194, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 46, "http://www.canfite.com/20230630": 1, "http://xbrl.sec.gov/dei/2023": 5, "total": 52 }, "keyCustom": 4, "keyStandard": 123, "memberCustom": 4, "memberStandard": 13, "nsprefix": "canf", "nsuri": "http://www.canfite.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "ea184381-6k_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.canfite.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "ea184381-6k_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "10", "role": "http://www.canfite.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:CondensedFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Unaudited Condensed Financial Statements", "menuCat": "Notes", "order": "11", "role": "http://www.canfite.com/role/UnauditedCondensedFinancialStatements", "shortName": "Unaudited Condensed Financial Statements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "srt:CondensedFinancialStatementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Deferred Revenues", "menuCat": "Notes", "order": "12", "role": "http://www.canfite.com/role/DeferredRevenues", "shortName": "Deferred Revenues", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredRevenueDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "13", "role": "http://www.canfite.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Earning Per Share", "menuCat": "Notes", "order": "14", "role": "http://www.canfite.com/role/EarningPerShare", "shortName": "Earning Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Shareholders Equity", "menuCat": "Notes", "order": "15", "role": "http://www.canfite.com/role/ShareholdersEquity", "shortName": "Shareholders Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "16", "role": "http://www.canfite.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Earning Per Share (Tables)", "menuCat": "Tables", "order": "17", "role": "http://www.canfite.com/role/EarningPerShareTables", "shortName": "Earning Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Shareholders Equity (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.canfite.com/role/ShareholdersEquityTables", "shortName": "Shareholders Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - General (Details)", "menuCat": "Details", "order": "19", "role": "http://www.canfite.com/role/GeneralDetails", "shortName": "General (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.canfite.com/role/ConsolidatedBalanceSheet", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DeferredRevenueDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepositContractsLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Deferred Revenues (Details)", "menuCat": "Details", "order": "20", "role": "http://www.canfite.com/role/DeferredRevenuesDetails", "shortName": "Deferred Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DeferredRevenueDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DepositContractsLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value", "menuCat": "Details", "order": "21", "role": "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable", "shortName": "Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c30", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share", "menuCat": "Details", "order": "22", "role": "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable", "shortName": "Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share (Parentheticals)", "menuCat": "Details", "order": "23", "role": "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable_Parentheticals", "shortName": "Earning Per Share (Details) - Schedule of Computation of Basic and Diluted Net Loss Per Share (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Earning Per Share (Details) - Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders", "menuCat": "Details", "order": "24", "role": "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable", "shortName": "Earning Per Share (Details) - Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c42", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityOtherShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Shareholders Equity (Details)", "menuCat": "Details", "order": "25", "role": "http://www.canfite.com/role/ShareholdersEquityDetails", "shortName": "Shareholders Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c42", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityOtherShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Shareholders Equity (Details) - Schedule of Share Options and Their Weighted Average Exercise Price", "menuCat": "Details", "order": "26", "role": "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable", "shortName": "Shareholders Equity (Details) - Schedule of Share Options and Their Weighted Average Exercise Price", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.canfite.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.canfite.com/role/ConsolidatedIncomeStatement", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://www.canfite.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c16", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.canfite.com/role/ShareholdersEquityType2or3", "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c16", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "7", "role": "http://www.canfite.com/role/ShareholdersEquityType2or3_Parentheticals", "shortName": "Condensed Consolidated Statements of Changes in Equity (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c1", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredFinanceCostsNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "8", "role": "http://www.canfite.com/role/ConsolidatedCashFlow", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - General", "menuCat": "Notes", "order": "9", "role": "http://www.canfite.com/role/General", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "ea184381ex99-2_canfitebio.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 17, "tag": { "canf_CashFlowsFromOperatingActivities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Flows From Operating Activities", "terseLabel": "Cash flows from operating activities" } } }, "localname": "CashFlowsFromOperatingActivities", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/GeneralDetails" ], "xbrltype": "monetaryItemType" }, "canf_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator Abstract", "terseLabel": "Denominator:" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable" ], "xbrltype": "stringItemType" }, "canf_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.canfite.com/20230630", "xbrltype": "stringItemType" }, "canf_FairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements (Details) - Schedule of Financial Assets and Liabilities Measured at Fair Value [Table]" } } }, "localname": "FairValueMeasurementsDetailsScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "stringItemType" }, "canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment": { "auth_ref": [], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of changes in fair value of short-term investment.", "label": "Increase Decrease In Changes In Fair Value Of Shortterm Investment", "negatedLabel": "Changes in fair value of short-term investment" } } }, "localname": "IncreaseDecreaseInChangesInFairValueOfShorttermInvestment", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "canf_LeaseLiabilitiesArisingFromObtainingRightofuseassets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease liabilities arising from obtaining right-of-use-assets.", "label": "Lease Liabilities Arising From Obtaining Rightofuseassets", "terseLabel": "Lease liabilities arising from obtaining right-of-use-assets" } } }, "localname": "LeaseLiabilitiesArisingFromObtainingRightofuseassets", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "canf_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator Abstract", "terseLabel": "Numerator:" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable" ], "xbrltype": "stringItemType" }, "canf_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options Member", "terseLabel": "Options [Member]" } } }, "localname": "OptionsMember", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable" ], "xbrltype": "domainItemType" }, "canf_PrefundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prefunded Warrants Member", "terseLabel": "Pre-funded Warrants [Member]" } } }, "localname": "PrefundedWarrantsMember", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "canf_RDSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RDShares Member", "terseLabel": "RD Shares [Member]" } } }, "localname": "RDSharesMember", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "canf_ScheduleOfComputationOfBasicAndDilutedNetLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Computation of Basic and Diluted Net Loss Per Share [Abstract]" } } }, "localname": "ScheduleOfComputationOfBasicAndDilutedNetLossPerShareAbstract", "nsuri": "http://www.canfite.com/20230630", "xbrltype": "stringItemType" }, "canf_ScheduleOfComputationOfDilutedNetLossPerShareAttributableToOrdinaryShareholdersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders [Abstract]" } } }, "localname": "ScheduleOfComputationOfDilutedNetLossPerShareAttributableToOrdinaryShareholdersAbstract", "nsuri": "http://www.canfite.com/20230630", "xbrltype": "stringItemType" }, "canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Financial Assets And Liabilities Measured At Fair Value Abstract" } } }, "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueAbstract", "nsuri": "http://www.canfite.com/20230630", "xbrltype": "stringItemType" }, "canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Financial Assets and Liabilities Measured at Fair Value [Line Items]" } } }, "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueLineItems", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "stringItemType" }, "canf_ScheduleOfShareOptionsAndTheirWeightedAverageExercisePriceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Share Options and Their Weighted Average Exercise Price [Abstract]" } } }, "localname": "ScheduleOfShareOptionsAndTheirWeightedAverageExercisePriceAbstract", "nsuri": "http://www.canfite.com/20230630", "xbrltype": "stringItemType" }, "canf_ShareholdersEquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders Equity (Details) [Line Items]" } } }, "localname": "ShareholdersEquityDetailsLineItems", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "canf_ShareholdersEquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders Equity (Details) [Table]" } } }, "localname": "ShareholdersEquityDetailsTable", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "canf_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants Member", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable" ], "xbrltype": "domainItemType" }, "canf_WeightedAverageRemainingContractualTermsEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual terms.", "label": "Weighted Average Remaining Contractual Terms Ending", "terseLabel": "Weighted average remaining contractual terms, Ending" } } }, "localname": "WeightedAverageRemainingContractualTermsEnding", "nsuri": "http://www.canfite.com/20230630", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "durationItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.canfite.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Leader of board of directors.", "label": "Board of Directors Chairman [Member]", "terseLabel": "Board of Directors Chairman [Member]" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unaudited Condensed Financial Statements [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2023", "xbrltype": "stringItemType" }, "srt_CondensedFinancialStatementsTextBlock": { "auth_ref": [ "r66", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for condensed financial statements.", "label": "Condensed Financial Statements [Text Block]", "terseLabel": "UNAUDITED CONDENSED FINANCIAL STATEMENTS" } } }, "localname": "CondensedFinancialStatementsTextBlock", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/UnauditedCondensedFinancialStatements" ], "xbrltype": "textBlockItemType" }, "srt_MaximumMember": { "auth_ref": [ "r145", "r146", "r147", "r148", "r182", "r230", "r245", "r272", "r273", "r325", "r326", "r327", "r328", "r329", "r336", "r337", "r341", "r344", "r348", "r350", "r386", "r395", "r396", "r397", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r145", "r146", "r147", "r148", "r182", "r230", "r245", "r272", "r273", "r325", "r326", "r327", "r328", "r329", "r336", "r337", "r341", "r344", "r348", "r350", "r386", "r395", "r396", "r397", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r145", "r146", "r147", "r148", "r175", "r182", "r189", "r190", "r191", "r229", "r230", "r245", "r272", "r273", "r325", "r326", "r327", "r328", "r329", "r336", "r337", "r341", "r344", "r348", "r350", "r353", "r383", "r386", "r396", "r397", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r145", "r146", "r147", "r148", "r175", "r182", "r189", "r190", "r191", "r229", "r230", "r245", "r272", "r273", "r325", "r326", "r327", "r328", "r329", "r336", "r337", "r341", "r344", "r348", "r350", "r353", "r383", "r386", "r396", "r397", "r398", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r381", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [ "r275" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable and Other Accrued Liabilities", "terseLabel": "Other accounts payable" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r11", "r12" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r17", "r18", "r44", "r75", "r239", "r250", "r251" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r1", "r6", "r18", "r203", "r206", "r225", "r246", "r247", "r369", "r370", "r371", "r376", "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r39", "r349", "r406" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r192", "r193", "r194", "r260", "r376", "r377", "r378", "r390", "r407" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r118" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Options" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r61", "r71", "r89", "r125", "r131", "r135", "r140", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r198", "r200", "r215", "r236", "r294", "r349", "r360", "r384", "r385", "r393" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r69", "r76", "r89", "r140", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r198", "r200", "r215", "r349", "r384", "r385", "r393" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r89", "r140", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r198", "r200", "r215", "r384", "r385", "r393" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "NON-CURRENT ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r21", "r51", "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r51" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r364", "r402" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosures of noncash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r65", "r72", "r73", "r74", "r89", "r108", "r112", "r115", "r117", "r123", "r124", "r140", "r149", "r151", "r152", "r153", "r156", "r157", "r160", "r161", "r163", "r166", "r172", "r215", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r282", "r303", "r320", "r330", "r331", "r332", "r333", "r334", "r362", "r374", "r379" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Purchase of warrant" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r14", "r29", "r237", "r281" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "CONTIGENT LIABILITIES AND COMMITMENTS" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Future grant shares" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r351", "r352", "r353", "r355", "r356", "r357", "r358", "r376", "r377", "r390", "r405", "r407" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Ordinary shares" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r38", "r282" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r38", "r282", "r300", "r407", "r408" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Ordinary shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r38", "r238", "r349" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Ordinary shares of no-par value - Authorized: 5,000,000,000 shares at June 30, 2023 and December 31, 2022; Issued and outstanding: 1,224,837,393 and 815,746,293 shares as of June 30, 2023 and December 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssued": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Number of common units issued of limited liability company (LLC).", "label": "Common Unit, Issued", "terseLabel": "Issuance of ordinary share" } } }, "localname": "CommonUnitIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r46" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "terseLabel": "Financial expenses (income), net" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r22", "r23" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Warrants or Options Issued", "terseLabel": "Warrants" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r28", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Net of issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3_Parentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeRevenueRecognized": { "auth_ref": [ "r403", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized previously reported as deferred income not accounted for under Topic 606.", "label": "Deferred Income, Revenue Recognized", "terseLabel": "Recognized revenues" } } }, "localname": "DeferredIncomeRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/DeferredRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r365" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenues" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueDisclosureTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.", "label": "Deferred Revenue Disclosure [Text Block]", "terseLabel": "DEFERRED REVENUES" } } }, "localname": "DeferredRevenueDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/DeferredRevenues" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r366" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenues" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositContractsLiabilities": { "auth_ref": [ "r143", "r144" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of liabilities as of the balance sheet date pertaining to amounts received by the insurer or reinsurer from the insured (including a ceding company) under insurance or reinsurance contracts for which insurance risk is not transferred.", "label": "Deposit Contracts, Liabilities", "terseLabel": "Contract liabilities" } } }, "localname": "DepositContractsLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/DeferredRevenuesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssetsCurrent": { "auth_ref": [ "r367" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.", "label": "Deposits Assets, Current", "terseLabel": "Short term deposits" } } }, "localname": "DepositsAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r4", "r128" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation of property, plant and equipment" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r83", "r96", "r97", "r98", "r99", "r100", "r105", "r108", "r115", "r116", "r117", "r121", "r210", "r211", "r232", "r244", "r339" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net loss per share (in Dollars per share)", "verboseLabel": "Basic net loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement", "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r83", "r96", "r97", "r98", "r99", "r100", "r108", "r115", "r116", "r117", "r121", "r210", "r211", "r232", "r244", "r339" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net loss per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r104", "r118", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNING PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/EarningPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r216" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Exchange differences on balances of cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r7", "r67", "r79", "r80", "r81", "r91", "r92", "r93", "r95", "r101", "r103", "r122", "r141", "r142", "r174", "r192", "r193", "r194", "r196", "r197", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r246", "r247", "r248", "r260", "r320" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable", "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of excess stock shares permitted to be issued.", "label": "Excess Stock, Shares Authorized", "terseLabel": "Exercisable ordinary shares" } } }, "localname": "ExcessStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ExcessStockSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.", "label": "Excess Stock, Shares Issued", "terseLabel": "Exercised pre-funded warrants" } } }, "localname": "ExcessStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ExcessStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of excess stock held by shareholders.", "label": "Excess Stock, Shares Outstanding", "terseLabel": "Unlisted options exercisable price" } } }, "localname": "ExcessStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r158", "r176", "r177", "r178", "r179", "r180", "r181", "r214", "r226", "r227", "r228", "r342", "r343", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel12And3Member": { "auth_ref": [ "r388" ], "lang": { "en-us": { "role": { "documentation": "Fair value measurement input including quoted price in active market for identical asset or liability reporting entity can access at measurement date (level 1), input other than quoted price included within level 1 either directly or indirectly observable for asset or liability (level 2) and unobservable input reflecting entity's own assumption (level 3).", "label": "Fair Value, Inputs, Level 1, Level 2, and Level 3 [Member]", "terseLabel": "Fair value [Member]" } } }, "localname": "FairValueInputsLevel12And3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r158", "r176", "r181", "r214", "r226", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r158", "r176", "r181", "r214", "r227", "r342", "r343", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r158", "r176", "r177", "r178", "r179", "r180", "r181", "r214", "r228", "r342", "r343", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsNonrecurringValueMeasurementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Measurements [Abstract]" } } }, "localname": "FairValueMeasurementsNonrecurringValueMeasurementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FiscalPeriodDuration": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Duration of a fiscal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but not limited to, weeks in a year or quarter.", "label": "Fiscal Period Duration", "terseLabel": "Period of grant" } } }, "localname": "FiscalPeriodDuration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r47", "r305" ], "calculation": { "http://www.canfite.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r3" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Decrease in trade payables" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r338" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Decrease in deferred revenues" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r363", "r372" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Decrease in operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "auth_ref": [ "r3" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Increase (Decrease) in Other Accounts Payable", "terseLabel": "Decrease in other accounts payable" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r3" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Change in prepaid expenses, and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r109", "r110", "r111", "r117" ], "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "terseLabel": "Total" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable" ], "xbrltype": "sharesItemType" }, "us-gaap_InsuranceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenues [Abstract]" } } }, "localname": "InsuranceAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r43", "r62", "r241", "r349", "r375", "r382", "r391" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r70", "r89", "r140", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r199", "r200", "r201", "r215", "r349", "r384", "r393", "r394" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r10", "r33", "r34", "r35", "r36", "r89", "r140", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r199", "r200", "r201", "r215", "r384", "r393", "r394" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "NON-CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r51", "r52", "r53" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r45", "r53", "r63", "r68", "r77", "r78", "r81", "r89", "r94", "r96", "r97", "r98", "r99", "r102", "r103", "r113", "r125", "r130", "r134", "r136", "r140", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r211", "r215", "r243", "r302", "r318", "r319", "r340", "r359", "r384" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.canfite.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net losses" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow", "http://www.canfite.com/role/ConsolidatedIncomeStatement", "http://www.canfite.com/role/GeneralDetails", "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r84", "r96", "r97", "r98", "r99", "r105", "r106", "r114", "r117", "r125", "r130", "r134", "r136", "r340" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss applicable to shareholders of Ordinary Shares" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r48" ], "calculation": { "http://www.canfite.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Total financial income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r125", "r130", "r134", "r136", "r340" ], "calculation": { "http://www.canfite.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r224" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current maturity of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r224" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long - term operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r223" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r373" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Reduction in the carrying amount of operating lease right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r32", "r60", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "GENERAL" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/General" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherShortTermInvestments": { "auth_ref": [ "r30", "r235", "r367" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term investments classified as other.", "label": "Other Short-Term Investments", "terseLabel": "Short-term investment", "verboseLabel": "Short-term equity investment" } } }, "localname": "OtherShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet", "http://www.canfite.com/role/ScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "terseLabel": "Issuance costs (in Dollars)" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r50" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r49" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Investment in short-term deposits" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r368" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r2" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of ordinary shares and warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r2" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of ordinary share due to exercise of warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": { "auth_ref": [ "r19", "r49" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments", "terseLabel": "Maturity of short-term deposits" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r5", "r234", "r242", "r349" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r31", "r195", "r401" ], "calculation": { "http://www.canfite.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r40", "r57", "r240", "r249", "r251", "r259", "r283", "r349" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r67", "r91", "r92", "r93", "r95", "r101", "r103", "r141", "r142", "r192", "r193", "r194", "r196", "r197", "r202", "r204", "r205", "r207", "r209", "r246", "r248", "r260", "r407" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r82", "r89", "r126", "r127", "r129", "r132", "r133", "r137", "r138", "r139", "r140", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r215", "r233", "r384" ], "calculation": { "http://www.canfite.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Placement agent warrants" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Computation of Diluted Net Loss Per Share Attributable to Ordinary Shareholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/EarningPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/EarningPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r213", "r214" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r8", "r9", "r26" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Share Options and Their Weighted Average Exercise Price" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series B.", "label": "Series A [Member]", "terseLabel": "Series A [Member]" } } }, "localname": "SeriesAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series A.", "label": "Series B [Member]", "terseLabel": "Series B [Member]" } } }, "localname": "SeriesBMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r3" ], "calculation": { "http://www.canfite.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Number of options, Forfeited/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Forfeited/expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of options, Grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Beginning", "verboseLabel": "Aggregate intrinsic value, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of options, Ending", "periodStartLabel": "Number of options, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, Ending", "periodStartLabel": "Weighted average exercise price, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "auth_ref": [ "r188" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Number of options, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Number of options, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, Grants" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Purchase price (in Dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r25" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual terms, Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual terms, Vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual terms, Exercisable" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofShareOptionsandTheirWeightedAverageExercisePriceTable" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Number of ordinary shares in each ADS (in Shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/GeneralDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r54", "r87" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r65", "r72", "r73", "r74", "r89", "r108", "r112", "r115", "r117", "r123", "r124", "r140", "r149", "r151", "r152", "r153", "r156", "r157", "r160", "r161", "r163", "r166", "r172", "r215", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r282", "r303", "r320", "r330", "r331", "r332", "r333", "r334", "r362", "r374", "r379" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r7", "r16", "r67", "r79", "r80", "r81", "r91", "r92", "r93", "r95", "r101", "r103", "r122", "r141", "r142", "r174", "r192", "r193", "r194", "r196", "r197", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r217", "r218", "r219", "r220", "r221", "r222", "r225", "r246", "r247", "r248", "r260", "r320" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofDilutedNetLossPerShareAttributabletoOrdinaryShareholdersTable", "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r91", "r92", "r93", "r122", "r231", "r254", "r271", "r274", "r276", "r277", "r278", "r279", "r280", "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r320", "r354" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r91", "r92", "r93", "r122", "r231", "r254", "r271", "r274", "r276", "r277", "r278", "r279", "r280", "r282", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r298", "r299", "r301", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r320", "r354" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of ordinary shares due to exercise of warrants (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r7", "r37", "r38", "r57", "r186" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Issuance of ordinary shares and warrants, net of issuance costs of $ 973 (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of ordinary shares due to exercise of warrants" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r27", "r37", "r38", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Share-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r7", "r16", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of ordinary shares and warrants, net of issuance costs of $ 973" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionExercisePriceDecrease": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Per share decrease in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.", "label": "Stock Option, Exercise Price, Decrease", "terseLabel": "Exercise price per share (in Dollars per share)" } } }, "localname": "StockOptionExercisePriceDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r38", "r41", "r42", "r55", "r284", "r300", "r321", "r322", "r349", "r360", "r375", "r382", "r391", "r407" ], "calculation": { "http://www.canfite.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet", "http://www.canfite.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS\u2019 EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders Equity [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r56", "r88", "r159", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r174", "r208", "r323", "r324", "r335" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "SHAREHOLDERS EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "terseLabel": "Aggregate ordinary shares" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WarrantExercisePriceDecrease": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Decrease", "terseLabel": "Exercise price" } } }, "localname": "WarrantExercisePriceDecrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WarrantExercisePriceIncrease": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Increase", "terseLabel": "Warrant exercise price (in Dollars per share)" } } }, "localname": "WarrantExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ShareholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r107", "r117" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of ordinary shares used in computing diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r105", "r117" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share (in Shares)", "verboseLabel": "Weighted average number of ordinary shares used in computing basic net loss per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.canfite.com/role/ConsolidatedIncomeStatement", "http://www.canfite.com/role/ScheduleofComputationofBasicandDilutedNetLossPerShareTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483081/340-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483054/340-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(10)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.5)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r361": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "430", "URI": "https://asc.fasb.org//430/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r65": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "a", "Publisher": "SEC", "Section": "12", "Subsection": "04", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.B)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 44 0001213900-23-072599-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-072599-xbrl.zip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end